Sirolimus monotherapy following Campath-1H induction.

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Maintenance immunosuppression is crucial for kidney transplant success.
• Steroid- and calcineurin inhibitor-based regimens have significant side effects.
• Sirolimus offers a potential alternative for immunosuppression.

Purpose of the Study:

• To evaluate sirolimus as a single agent for maintenance immunosuppression in kidney transplant recipients.
• To assess the dose, blood levels, and side effect profile of sirolimus monotherapy.
• To analyze rejection rates and cardiovascular risk factors under sirolimus monotherapy.

Main Methods:

• A pilot trial involving 29 primary kidney transplant patients.
• Lymphocyte depletion with Campath-1H was used for induction.
• Sirolimus was administered as the sole maintenance immunosuppressant, excluding steroids and calcineurin inhibitors.

Main Results:

• A sirolimus dose of 4 mg/day achieved blood levels of 8-9 ng/mL.
• The overall rejection rate was 28%, with no significant difference in sirolimus levels between rejected and non-rejected patients.
• Cardiovascular risk profile was favorable, with manageable hypertension and transient lipid level increases.
• Sirolimus monotherapy was generally well-tolerated, with no significant issues in wound healing, leukopenia, or anemia.

Conclusions:

• Sirolimus monotherapy demonstrated a well-tolerated side effect profile in kidney transplant patients.
• The observed 28% rejection rate suggests that current dosing or patient selection may require optimization.
• Further investigation is warranted to refine sirolimus monotherapy protocols for optimal efficacy and safety in kidney transplantation.